Are you Dr. Coughlin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 45 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
34th & Civic Center Blvd
Children's Hospital Of Philadelphia
Philadelphia, PA 19104Phone+1 215-590-1000Fax+1 215-561-0959
Summary
- Dr. Christina Coughlin, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2001 - 2004- Children's Hospital of PhiladelphiaResidency, Pediatrics, 1999 - 2001
Perelman School of Medicine at the University of PennsylvaniaClass of 1999
Certifications & Licensure
PA State Medical License 2001 - 2014
Clinical Trials
- RTX-240 Monotherapy and in Combination With Pembrolizumab Start of enrollment: 2020 May 06
Publications & Presentations
PubMed
- 47 citationsA First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid TumorsLuis A. Diaz, Christina M. Coughlin, Susan C. Weil, Jean Fishel, Mrinal M. Gounder
Clinical Cancer Research. 2015-03-15 - 57 citationsCD40-Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's LymphomaKarin U. Sorenmo, Erika L. Krick, Christina M. Coughlin, Beth Overley, Thomas P. Gregor
Plos One. 2011-08-31 - 20 citationsApproaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapyChristina Marie Coughlin, Daniel S. Johnston, Andrew Strahs, Michael E. Burczynski, Sarah S. Bacus
Breast Cancer Research and Treatment. 2010-08-28
Press Mentions
- CytoImmune Therapeutics Appoints Remus Vezan, M.D., Ph.D., as Chief Medical OfficerSeptember 7th, 2022
- CytoImmune to Present New Preclinical Data Highlighting Potential of Novel TRACK-NK Cell Therapies as Treatments for Both Solid Tumors and Hematologic MalignanciesMarch 8th, 2022
- City of Hope and CytoImmune Announce Study Demonstrating Novel Off-the-Shelf Chimeric Antigen Receptor (CAR) Natural Killer (NK) Cell-Based Therapy Against Pancreatic CancerJanuary 18th, 2022
- Join now to see all
